KALA
KALA BIO, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.17
−4.05%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$0.17
From 52W high−99.75%
Volume212751.00
Market cap$3.25M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 30, 2026
Open
$0.17
From 52W high
−99.75%
Volume
212751.00
Market cap
$3.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
20.7
MomentumView details →
1D Return
−4.05%
YTD Return
−99.41%
SummaryUpdated Jun 1, 2026
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is a biopharmaceutical company founded in 2009 and headquartered in Watertown, Massachusetts. The company was originally incorporated as Hanes Newco, Inc. before changing its name in December 2009 and went public in July 2017. Kala has undergone significant strategic transformation in recent years, transitioning from a commercial-stage company with marketed eye care products to a research-focused organization developing novel therapies for ocular diseases using proprietary drug delivery technologies.
Similar companies
Latest newsMore news →
KALA Bio signed a non-binding letter of intent to acquire 100% of a privately held U.S.-based management services organization supporting a 50-state telehealth platform for approximately $15 million in cash and KALA stock.31d agoKala Bio and Virotek signed a letter of intent with a U.S. DNA testing platform to resell Virotek's suite of genetic testing products, expanding their genetic testing collaboration beyond ophthalmology.36d agoKALA BIO, Inc. signed an exclusive distribution and reseller agreement with Virotek Inc. to distribute Virotek's ophthalmology genetic testing program in the United States for an initial five-year term.50d ago